Holen Sie sich die Stockscreener-App
4.34
2.60%
0.11
Schlusskurs vom Vortag:
$4.23
Offen:
$4.2
24-Stunden-Volumen:
400.94K
Relative Volume:
0.60
Marktkapitalisierung:
$241.30M
Einnahmen:
$163.78M
Nettoeinkommen (Verlust:
$25.88M
KGV:
6.6769
EPS:
0.65
Netto-Cashflow:
$-28.66M
1W Leistung:
+7.69%
1M Leistung:
+4.33%
6M Leistung:
+30.72%
1J Leistung:
-31.00%
1-Tages-Spanne:
$4.17
$4.44
1-Wochen-Bereich:
$3.735
$4.44
52-Wochen-Spanne:
$2.645
$6.69
Voyager Therapeutics Inc Stock (VYGR) Company Profile
Firmenname
Voyager Therapeutics Inc
Sektor
Branche
Telefon
857-259-5340
Adresse
75 HAYDEN AVENUE, LEXINGTON, MA
Vergleichen Sie VYGR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VYGR
Voyager Therapeutics Inc
|
4.34 | 235.19M | 163.78M | 25.88M | -28.66M | 0.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Voyager Therapeutics Inc Stock (VYGR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-12-02 | Eingeleitet | Citigroup | Buy |
| 2024-11-29 | Fortgesetzt | Wedbush | Outperform |
| 2024-10-16 | Eingeleitet | Leerink Partners | Outperform |
| 2024-03-26 | Eingeleitet | Guggenheim | Buy |
| 2024-03-19 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-03-07 | Eingeleitet | Citigroup | Buy |
| 2024-01-02 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-05-10 | Eingeleitet | Truist | Buy |
| 2023-03-10 | Eingeleitet | Oppenheimer | Outperform |
| 2021-10-07 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2021-02-26 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2021-02-03 | Herabstufung | BTIG Research | Buy → Neutral |
| 2021-02-03 | Herabstufung | Wedbush | Outperform → Neutral |
| 2020-12-24 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2020-12-23 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-11-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-11-10 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2020-11-10 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-03-19 | Eingeleitet | The Benchmark Company | Buy |
| 2020-02-06 | Eingeleitet | Oppenheimer | Outperform |
| 2018-11-15 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2018-09-10 | Fortgesetzt | BTIG Research | Buy |
| 2018-09-10 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2018-06-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-03-12 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2018-03-12 | Herabstufung | Wedbush | Outperform → Neutral |
| 2018-02-02 | Eingeleitet | Morgan Stanley | Overweight |
| 2017-11-28 | Fortgesetzt | Piper Jaffray | Overweight |
| 2017-10-31 | Eingeleitet | Robert W. Baird | Outperform |
| 2017-10-27 | Eingeleitet | Canaccord Genuity | Buy |
| 2017-10-23 | Bestätigt | Stifel | Buy |
| 2017-10-12 | Eingeleitet | Raymond James | Outperform |
| 2017-08-17 | Eingeleitet | Evercore ISI | Outperform |
| 2017-07-28 | Fortgesetzt | Stifel | Buy |
Alle ansehen
Voyager Therapeutics Inc Aktie (VYGR) Neueste Nachrichten
Ready to Jump After Recent Trade: Voyager Therapeutics Inc (VYGR) - Setenews
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Is Voyager Therapeutics Inc. stock undervalued vs historical averagesMarket Sentiment Report & AI Enhanced Execution Alerts - BỘ NỘI VỤ
Is Voyager Therapeutics Inc a good long term investmentPortfolio Risk Assessment & Budget Friendly Trading Strategies - earlytimes.in
A History of Outperforming Analyst Forecasts and Beating the Odds: Voyager Therapeutics Inc (VYGR) - Setenews
J&J Halts Alzheimer's Trial After Drug Fails To Slow Clinical Decline - Benzinga
We're A Little Worried About Voyager Therapeutics' (NASDAQ:VYGR) Cash Burn Rate - Yahoo Finance
Why Voyager Therapeutics Inc. stock is rated strong buyCEO Change & Smart Money Movement Alerts - newser.com
How Voyager Therapeutics Inc. stock performs in weak economyJuly 2025 Patterns & Reliable Volume Spike Alerts - newser.com
Will Voyager Therapeutics Inc. stock split again soonJuly 2025 Spike Watch & Risk Controlled Daily Trade Plans - newser.com
How rising interest rates impact Voyager Therapeutics Inc. stock2025 Dividend Review & Short-Term High Return Ideas - newser.com
Developing predictive dashboards with Voyager Therapeutics Inc. dataBreakout Watch & Free Growth Oriented Trading Recommendations - newser.com
Key resistance and support levels for Voyager Therapeutics Inc.2025 Technical Overview & Free Weekly Watchlist of Top Performers - newser.com
Using R and stats models for Voyager Therapeutics Inc. forecastingWeekly Stock Analysis & Free Safe Capital Growth Stock Tips - newser.com
What high frequency data says about Voyager Therapeutics Inc.2025 Volatility Report & Free Technical Confirmation Trade Alerts - newser.com
Can Voyager Therapeutics Inc. stock hit record highs again2025 Market Trends & Weekly Watchlist for Hot Stocks - newser.com
Sentiment analysis tools applied to Voyager Therapeutics Inc.Earnings Summary Report & Free Safe Capital Growth Stock Tips - newser.com
FY2025 Earnings Forecast for VYGR Issued By HC Wainwright - Defense World
What drives Voyager Therapeutics Inc stock priceHigh Dividend Yield Stocks & Outstanding Growth Strategies - earlytimes.in
Benign Growth For Voyager Therapeutics, Inc. (NASDAQ:VYGR) Underpins Stock's 26% Plummet - simplywall.st
Finanzdaten der Voyager Therapeutics Inc-Aktie (VYGR)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.10%
1.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):